🚨 SUPN: Supernus and Indivior Forge a $2.2B CNS Powerhouse Through Merger of Equals, Backed by a $1B Special Dividend

New Filing: 8-K

Ticker: SUPN | Score: 10/10 | Sentiment: Positive

Summary (Wiseek AI)

Supernus and Indivior are merging in an all-stock deal, creating a CNS biopharma leader with $2.2B in combined revenue. Indivior stockholders get a $1B special dividend; Supernus stockholders get 1.5401 Indivior shares per share. The combined company will be led by Supernus CEO Jack Khattar.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.